These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 25305590)

  • 1. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
    Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E
    J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib.
    Yerlikaya A; Okur E; Ulukaya E
    Tumour Biol; 2012 Oct; 33(5):1385-92. PubMed ID: 22477712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Data for a proteomic analysis of p53-independent induction of apoptosis by bortezomib.
    Yerlikaya A; Okur E; Tarık Baykal A; Acılan C; Boyacı İ; Ulukaya E
    Data Brief; 2014 Dec; 1():56-9. PubMed ID: 26217687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
    Yerlikaya A; Erin N
    Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
    Ooi MG; Hayden PJ; Kotoula V; McMillin DW; Charalambous E; Daskalaki E; Raje NS; Munshi NC; Chauhan D; Hideshima T; Buon L; Clynes M; O'Gorman P; Richardson PG; Mitsiades CS; Anderson KC; Mitsiades N
    Clin Cancer Res; 2009 Dec; 15(23):7153-60. PubMed ID: 19934289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.
    Yerlikaya A; DoKudur H
    Mol Biol (Mosk); 2010; 44(5):859-66. PubMed ID: 21090173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of heme oxygenase-1 in response to proteasomal inhibition.
    Yerlikaya A
    Protein Pept Lett; 2012 Dec; 19(12):1330-3. PubMed ID: 22670665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
    Yu J; Tiwari S; Steiner P; Zhang L
    Cancer Biol Ther; 2003; 2(6):694-9. PubMed ID: 14688479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
    Ling YH; Liebes L; Zou Y; Perez-Soler R
    J Biol Chem; 2003 Sep; 278(36):33714-23. PubMed ID: 12821677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function.
    Zhu Z; Ramos J; Kampa K; Adimoolam S; Sirisawad M; Yu Z; Chen D; Naumovski L; Lopez CD
    J Biol Chem; 2005 Oct; 280(41):34473-80. PubMed ID: 16091363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
    Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
    Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of bortezomib-adapted I-45 mesothelioma cells.
    Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
    Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
    Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
    Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
    An WG; Hwang SG; Trepel JB; Blagosklonny MV
    Leukemia; 2000 Jul; 14(7):1276-83. PubMed ID: 10914553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
    Obeng EA; Carlson LM; Gutman DM; Harrington WJ; Lee KP; Boise LH
    Blood; 2006 Jun; 107(12):4907-16. PubMed ID: 16507771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
    Biskup E; Kamstrup MR; Manfé V; Gniadecki R
    Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
    Nikiforov MA; Riblett M; Tang WH; Gratchouck V; Zhuang D; Fernandez Y; Verhaegen M; Varambally S; Chinnaiyan AM; Jakubowiak AJ; Soengas MS
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19488-93. PubMed ID: 18042711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
    Cascone T; Morelli MP; Morgillo F; Kim WY; Rodolico G; Pepe S; Tortora G; Berrino L; Lee HY; Heymach JV; Ciardiello F
    J Cell Physiol; 2008 Sep; 216(3):698-707. PubMed ID: 18381602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.